Form 4: ANAB CEO Faga Reports RSU Vesting, Stock Option Grant

AnaptysBio CEO Daniel Faga reported the vesting of restricted stock units, a subsequent 'sell to cover' transaction for tax obligations, and new grants of restricted stock units and stock options.

Summary

• Daniel Faga, President, CEO, and Director of AnaptysBio, Inc. (ANAB), reported transactions on January 6 and 7, 2026.
• On January 6, 2026, 17,850 shares of common stock were acquired due to the settlement of previously granted Restricted Stock Units (RSUs).
• Following this, on January 7, 2026, 9,202 shares of common stock were sold at a price of $45.11 per share to cover tax withholding obligations related to the RSU vesting. This was a non-discretionary 'sell to cover' transaction.
• Additionally, on January 6, 2026, Mr. Faga was granted 98,600 new Restricted Stock Units (RSUs) and 133,400 new stock options.
• The new RSUs will vest 25% annually starting January 6, 2027, and the new stock options will vest 25% on January 6, 2027, followed by monthly vesting of 1/48 of the total shares until fully vested, with an exercise price of $43.91 and an expiration date of January 5, 2036.
• After these transactions, Mr. Faga beneficially owns 466,787 shares of common stock directly.

Sentiment

Score: 7

Explanation: The filing indicates significant new equity grants (RSUs and stock options) to the CEO, which are generally viewed positively as they align management's long-term interests with shareholder value. The share sale was non-discretionary for tax purposes, thus neutral.

Positives

• Grant of 98,600 new Restricted Stock Units (RSUs) to the CEO, aligning management incentives with shareholder value.
• Grant of 133,400 new stock options with an exercise price of $43.91, providing long-term incentive for the CEO.
• The vesting of 17,850 RSUs indicates the achievement of prior performance or service conditions.

Negatives

• The sale of 9,202 shares of common stock, although for tax withholding purposes, reduces the CEO's direct beneficial ownership.

Future Outlook

NA

Industry Context

This Form 4 filing details routine executive compensation transactions, including RSU vesting, a tax-related share sale, and new equity grants. Such transactions are common across the biotechnology and pharmaceutical industries as a standard component of executive incentive and retention programs, aligning leadership interests with long-term company performance.

Stakeholder Impact

• Shareholders: The grants of new equity incentives to the CEO could be seen as positive for long-term alignment of interests. The 'sell to cover' transaction is a minor, non-discretionary share reduction.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Continued vesting of 98,600 RSUs annually commencing January 6, 2027.
• Continued vesting of 133,400 stock options, with 25% on January 6, 2027, and monthly thereafter.

Key Dates

Recommendation

The filing details routine executive compensation activities, including new equity grants and a tax-related share sale. While the grants are a positive signal for management alignment, the 'sell to cover' is a neutral event. This Form 4 alone does not provide sufficient information to warrant a 'buy' or 'sell' recommendation, suggesting a 'hold' as investors await broader company performance updates.

Keywords

AnaptysBio, ANAB, SEC Form 4, Insider Trading, Restricted Stock Units, RSU, Stock Options, Executive Compensation, Daniel Faga, Sell to Cover, Beneficial Ownership